Becton, Dickinson and Company (BDX) to Release Earnings on Thursday

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) is scheduled to be releasing its earnings data before the market opens on Thursday, May 2nd. Analysts expect Becton, Dickinson and Company to post earnings of $2.96 per share for the quarter. Becton, Dickinson and Company has set its FY24 guidance at $12.82-13.86 EPS.Persons that are interested in participating in the company's earnings conference call can do so using this link.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its earnings results on Thursday, February 1st. The medical instruments supplier reported $2.68 earnings per share for the quarter, topping analysts' consensus estimates of $2.39 by $0.29. The firm had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.73 billion. Becton, Dickinson and Company had a net margin of 6.44% and a return on equity of 13.57%. The company's revenue was up 2.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.98 EPS. On average, analysts expect Becton, Dickinson and Company to post $13 EPS for the current fiscal year and $14 EPS for the next fiscal year.

Becton, Dickinson and Company Stock Down 1.4 %

Shares of NYSE:BDX traded down $3.36 during midday trading on Thursday, reaching $230.47. The company's stock had a trading volume of 885,091 shares, compared to its average volume of 1,375,185. The firm has a 50 day moving average of $239.62 and a 200-day moving average of $241.73. The firm has a market capitalization of $66.58 billion, a P/E ratio of 55.39, a PEG ratio of 1.94 and a beta of 0.43. The company has a quick ratio of 0.64, a current ratio of 1.08 and a debt-to-equity ratio of 0.56. Becton, Dickinson and Company has a 12-month low of $229.40 and a 12-month high of $287.32.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on BDX shares. Raymond James raised their target price on shares of Becton, Dickinson and Company from $269.00 to $275.00 and gave the stock an "outperform" rating in a report on Wednesday, January 3rd. Barclays upped their target price on shares of Becton, Dickinson and Company from $301.00 to $305.00 and gave the company an "overweight" rating in a report on Monday, February 5th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of "Moderate Buy" and a consensus target price of $280.00.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 282 shares of the business's stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $238.29, for a total value of $67,197.78. Following the sale, the senior vice president now owns 2,276 shares in the company, valued at approximately $542,348.04. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.31% of the company's stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.